Gh Research (GHRS) Stock
Clinical-stage developer of psychedelic-inspired mental health treatments. Here's the price, business snapshot, and what's worth knowing about Gh Research in October 2026.
GH Research plc (GHRS) is a clinical-stage biotechnology company developing novel therapeutics inspired by classic psychedelics for neuropsychiatric disorders, including major depressive disorder and suicidal ideation. The company’s pipeline focuses on proprietary formulations and dosing regimens intended to deliver therapeutic benefits while managing safety and tolerability; its assets are in clinical development. With a market capitalisation of approximately $791.5m, GH Research attracts investor interest because of its targeted approach and the wider resurgence of research into psychedelic-derived medicines. However, it remains an early-stage biopharma: outcomes depend on clinical trial results, regulatory review and commercial adoption. Investors should be aware of typical sector risks — binary trial catalysts, potential dilution from fund-raising, and variable timelines. This summary is for educational purposes only and not personal financial advice; suitability depends on an investor’s goals, risk tolerance and time horizon.
Gh Research (GHRS) Stock Forecast
Analyst price target, next 12 months
$38.92
+109.3% vs today's $18.59
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Gh Research have a consensus 12-month target of $38.92, above the current price of $18.59.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GH Research's stock, with a target price suggesting significant potential growth.
Financial Health
GH Research is showing strong financial performance with healthy cash flow and value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GHRS
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Focus on psychedelic-inspired candidates means clinical trial results can be significant catalysts, though outcomes are uncertain and timelines can shift.
Rising research interest
Growing scientific and investor attention on psychedelic-based treatments could support long-term interest, but regulatory and commercial adoption remain to be proven.
Key near-term catalysts
Upcoming trial readouts and regulatory interactions may move the share price; investors should note the binary nature of such events and associated volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.